Vimarsana
Biggest News Aggregation in the World

Jay Mei News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jay Mei. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jay Mei Today - Breaking & Trending Today

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day - Vimarsana News

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Published: November 17, 2023

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to...

Source: prnewswire.com
Related Topics:
South KoreaHong KongPeter QianJay MeiAsia PacificAntengene Corporation LimitedCompany AnnualAntengene CorporationMd Anderson Cancer CenterAntengene Shanghai OfficeHong Kong Stock ExchangeFamily ZhangChief MedicalCancer CenterCorporation LimitedPatients BeyondTaiwan ChinaHong Kong ChinaAnnual ReportHong Kong StockHealth Care Amp HospitalsMedical Pharmaceuticals Pharmaceuticals Clinical Trials Amp Medical DiscoveriesOlls And Research
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs - Vimarsana News

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

Published: November 8, 2023

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to...

Source: prnewswire.com
Related Topics:
South AustraliaUnited StatesBritish ColumbiaNew JerseyHong KongSouth KoreaBo ShanWestern AustraliaUnited KingdomCity OfJay MeiShehara MendisGodfrey GuoAnthonyj OlszanskiPeter QianAdnan KhattakBing HouAsia PacificCutaneous Oncology ProgramAntengene Shanghai OfficePrnewswire Antengene Corporation LimitedMelbourne HealthUniversity Of MedicineFox Chase Cancer CenterEarly Clinical Drug Development Phase
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 - Vimarsana News

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

Published: September 21, 2023

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to...

Source: prnewswire.com
Related Topics:
United StatesSouth KoreaHong KongJay MeiPeter QianAsia PacificHong Kong Stock ExchangeAntengene CorporationAntengene Corporation LimitedPrnewswire Antengene Corporation LimitedCompany AnnualUniversity Of Texas Md Anderson Cancer CenterAmerican Association For Cancer Research Annual MeetingCorporation LimitedInstitutional Review BoardCancer CenterFamily ZhangChief Medical OfficerAmerican AssociationCancer Research Annual MeetingPatients BeyondTaiwan ChinaHong Kong ChinaAnnual ReportHong Kong Stock
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline - Vimarsana News

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

Published: August 25, 2023

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months ended June 30, 2023, and...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesSouth KoreaJay MeiPeter QianAsia PacificHansoh PharmaHong Kong Stock ExchangeAntengene Corporation LimitedScientific Review CommitteeBank Balance To Provide RunwayCompany AnnualNational Reimbursement Drug ListMd Anderson Cancer CenterAntengene CorporationDrug AdministrationHong Kong ChinaAustralian Pharmaceutical Benefits SchemeCancer Drug ListOrphan Drug DesignationsCancer CenterAntengene Annual Rd DayNew Drug ApplicationStrong CashBank Balance
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China - Vimarsana News

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

Published: August 11, 2023

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and...

Source: prnewswire.com
Related Topics:
South KoreaHong KongHansoh PharmaJay MeiPeter QianAsia PacificCompany AnnualInternational Myeloma FoundationNational Reimbursement Drug ListHansoh Pharmaceutical Group Company Limited PharmaAntengene CorporationHong Kong Stock ExchangePrnewswire Antengene Corporation LimitedKaryopharm Therapeutics IncAntengene Corporation LimitedCorporation LimitedHansoh Pharmaceutical Group Company LimitedChief Executive OfficerGiven AntengeneYuan SunExecutive DirectorKaryopharm TherapeuticsHong Kong ChinaPatients BeyondTaiwan China